Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.

BASEL, SWITZERLAND - APR 17: Roche headquarters on April 19, 2013 in Basel, Switzerland. Rocheis a Swiss global pharma company that operates worldwide producing pharmaceuticals and diagnostics.

Hanmi Pharmaceutical Co. Ltd. has entered into an exclusive license agreement with Genentech Inc., a subsidiary of Roche, for the development and commercialization of Hanmi’s oral pan-RAF inhibitor HM95573 for solid tumors, in a major global deal worth up to $910m plus sales royalties to the South Korean firm.

Under the agreement, Genentech will obtain exclusive worldwide rights, excluding South Korea, to develop and commercialize HM95573. Hanmi will receive...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip